Home › Companies › Catalyst Pharmaceuticals, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Catalyst Pharmaceuticals, Inc.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated November 1, 2026.
Meeting of May 20, 2025: 9 items on Catalyst Pharmaceuticals, Inc.’s Form 8-K, filed May 23, 2025: 9 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore Catalyst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Catalyst Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard J. Daly | 87,947,782 | 1,372,592 | 102,057 | -- | 11,793,160 | 98% | Not verified | — |
| Elect Director: Patrick J. McEnany | 82,282,446 | 7,039,324 | 100,661 | -- | 11,793,160 | 92% | Not verified | — |
| Elect Director: Donald A. Denkhaus | 87,993,958 | 1,329,212 | 99,261 | -- | 11,793,160 | 99% | Not verified | — |
| Elect Director: Molly Harper | 88,259,042 | 1,040,685 | 122,704 | -- | 11,793,160 | 99% | Not verified | — |
| Elect Director: Tamar Thompson | 85,761,231 | 3,562,397 | 98,803 | -- | 11,793,160 | 96% | Not verified | — |
| Elect Director: David S. Tierney | 84,527,122 | 4,751,403 | 143,906 | -- | 11,793,160 | 95% | Not verified | — |
| 2. Approval of an amendment to our 2018 Stock Incentive Plan | 85,350,862 | 3,975,602 | 95,967 | -- | 11,793,160 | 96% | Not verified | — |
| 3. Approval, on an advisory basis, of the 2024 compensation of our named executive officers | 82,734,939 | 6,484,020 | 203,472 | -- | 11,793,160 | 93% | Not verified | — |
| 4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 99,942,142 | 1,211,668 | 61,781 | -- | -- | 99% | Not verified | — |
Source: Catalyst Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.
Each item below shows how the 389 asset managers that disclosed a Catalyst Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Catalyst Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect David S. Tierney, M.D. as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David S. Tierney”): 84,527,122 for, 4,751,403 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 42,696,336 for, 514,923 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,979 | 4,684 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Donald A. Denkhaus as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Donald A. Denkhaus”): 87,993,958 for, 1,329,212 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 43,065,158 for, 146,100 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,985 | 4,677 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Molly Harper as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Molly Harper”): 88,259,042 for, 1,040,685 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 43,194,560 for, 16,699 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,986 | 4,677 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 5 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect Patrick J. McEnany as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Patrick J. McEnany”): 82,282,446 for, 7,039,324 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 40,203,681 for, 3,007,578 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,984 | 4,678 | 0 | 0 | For |
| State Street | 63,822 | 2,889,954 | 0 | 0 | Against |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect Richard J. Daly as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard J. Daly”): 87,947,782 for, 1,372,592 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 43,200,911 for, 10,348 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,660 | 3 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect Tamar Thompson as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Tamar Thompson”): 85,761,231 for, 3,562,397 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 114 asset managers below reported 42,516,184 for, 695,075 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,231,829 | 582,131 | 0 | 0 | For |
| Vanguard | 8,240,980 | 4,683 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,815,752 | 96,214 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
1% of fund votes cast · no official result
The 110 asset managers below reported 522,658 for, 42,481,526 against, 57,208 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 12,813,960 | 0 | 0 | Against |
| Vanguard | 11,898 | 8,233,764 | 1 | 0 | Against |
| State Street | 5,108 | 2,948,668 | 0 | 0 | Against |
| Fidelity | 0 | 2,911,966 | 0 | 0 | Against |
| Dimensional | 0 | 1,600,257 | 0 | 0 | Against |
| TIAA | 0 | 1,236,505 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,202,971 | 0 | 0 | Against |
| Royce | 0 | 1,141,617 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 854,367 | 0 | 0 | Against |
| Invesco | 0 | 829,473 | 0 | 0 | Against |
| T. Rowe Price | 0 | 719,930 | 0 | 0 | Against |
| Waddell & Reed | 0 | 634,570 | 0 | 0 | Against |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 0 | 467,100 | 0 | 0 | Against |
| Goldman Sachs | 0 | 391,456 | 0 | 0 | Against |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 0 | 294,963 | 0 | 0 | Against |
| World Funds Trust | 0 | 266,124 | 0 | 0 | Against |
| Northern Trust | 0 | 263,318 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 257,889 | 0 | 0 | Against |
| SEI | 0 | 256,097 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 243,921 | 0 | 0 | Against |
| First Trust | 0 | 236,665 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 236,483 | 0 | 0 | Against |
| Jackson National | 0 | 224,018 | 0 | 0 | Against |
Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.
Combines 7 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 5 million shares.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“2. Approval of an amendment to our 2018 Stock Incentive Plan”): 85,350,862 for, 3,975,602 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 121 asset managers below reported 42,590,578 for, 687,524 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,656 | 7 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.
Combines 10 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the 2024 compensation of our named executive officers.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the 2024 compensation of our named executive officers”): 82,734,939 for, 6,484,020 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Catalyst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on pay” (2 managers, 498 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,978 | 4,685 | 0 | 0 | For |
| State Street | 2,952,581 | 1,195 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 0 | 829,473 | 0 | 0 | Against |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 245,744 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
Fund voting reports, all 112 managers: 41,406,192 for, 1,787,109 against, 108,148 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 5,128,898 | 37,458 | 0 | 0 | For |
| BlackRock | 4,710,517 | 27,382 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,755,989 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,598,901 | 0 | 0 | 0 | For |
| Fundsmith LLP | 0 | 2,151,274 | 0 | 0 | Against |
| Renaissance | 1,418,682 | 0 | 0 | 0 | For |
| Charles Schwab | 1,324,513 | 0 | 0 | 0 | For |
| Nuveen | 1,248,350 | 0 | 0 | 0 | For |
| Boston Partners | 1,176,609 | 0 | 0 | 0 | For |
| Northern Trust | 1,148,050 | 5,449 | 0 | 0 | For |
| Invesco | 0 | 1,066,045 | 0 | 0 | Against |
| T. Rowe Price | 1,044,048 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 950,798 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 942,298 | 0 | 0 | 0 | For |
| Goldman Sachs | 765,572 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 734,054 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 721,880 | 0 | 0 | Against |
| JUPITER ASSET MANAGEMENT LTD | 661,020 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 540,691 | 89,787 | 0 | 0 | Mixed |
| PRINCIPAL GLOBAL INVESTORS | 617,506 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 130,559 | 474,582 | 0 | 0 | Mixed |
| American Century | 0 | 526,569 | 0 | 0 | Against |
| OBERWEIS ASSET MANAGEMENT INC/ | 467,100 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 426,807 | 0 | 0 | 0 | For |
| Allianz | 0 | 423,958 | 0 | 0 | Against |
Institutional-manager reports, all 299 managers: 39,907,857 for, 7,181,227 against, 400 abstained, 4,342 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To ratify the selection of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 99,942,142 for, 1,211,668 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Catalyst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 114 asset managers below reported 43,084,022 for, 127,237 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,661 | 2 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 121,959,172 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.51% |
| 2 | Vanguard | 6.76% |
| 3 | State Street | 2.42% |
| 4 | Fidelity | 2.39% |
| 5 | Dimensional | 1.31% |
| 6 | TIAA | 1.01% |
| 7 | Charles Schwab | 0.99% |
| 8 | Royce | 0.94% |
| 9 | Pacer Funds Trust | 0.70% |
| 10 | Invesco | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 4.24% |
| 2 | BlackRock | 3.88% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 2.13% |
| 5 | Fundsmith LLP | 1.76% |
| 6 | Renaissance | 1.16% |
| 7 | Charles Schwab | 1.09% |
| 8 | Nuveen | 1.02% |
| 9 | Boston Partners | 0.96% |
| 10 | Northern Trust | 0.95% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.42% | 13F |
| Vanguard Group | 6.97% | 13F |
| State Street | 4.53% | 13F |
| Goldman Sachs | 2.57% | 13F |
| Deerfield Mgmt, L.P. | 2.57% | 13G |
| Renaissance Technologies | 2.42% | 13F |
| Geode Capital | 2.27% | 13F |
| Morgan Stanley | 1.96% | 13F |
| Dimensional Fund Advisors | 1.79% | 13F |
| Northern Trust | 1.22% | 13F |
Percentages above are of 121,959,172 shares outstanding, as reported by Catalyst Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Catalyst Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.
At Catalyst Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2025, in the 2024-2025 proxy season, 389 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,149 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the 2024 compensation of our named executive officers. — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Catalyst Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.
Catalyst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Download data (CSV): ballot items · votes by manager · column guide.